Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MaxCyte's gross profit for the
three
months ended in Jun. 2026 was $5.60 Mil. MaxCyte's gross profit for the trailing twelve months (TTM) ended in Jun. 2026 was $24.60 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. MaxCyte's gross profit for the
three
months ended in Jun. 2026 was $5.60 Mil. MaxCyte's Revenue for the
three
months ended in Jun. 2026 was $7.27 Mil. Therefore, MaxCyte's Gross Margin % for the quarter that ended in Jun. 2026 was 76.96%.
MaxCyte had a gross margin of 76.96% for the quarter that ended in Jun. 2026 => Durable competitive advantage
During the past 13 years, the highestGross Margin % of MaxCyte was 89.61%. The lowest was 80.51%. And the median was 88.74%.
Warning Sign:
MaxCyte Inc gross margin has been in long-term decline. The average rate of decline per year is -2.1%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
MaxCyte had a gross margin of 76.96% for the quarter that ended in Jun. 2026 => Durable competitive advantage
MaxCyte Gross Profit Related Terms
MaxCyte Gross Profit Historical Data
* Premium members only.
The historical data trend for MaxCyte's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, MaxCyte's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MaxCyte Gross Profit vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MaxCyte's Gross Profit distribution charts can be found below:
* The bar in red indicates where MaxCyte's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $24.60 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
MaxCyte (MXCT) has a Gross Profit of $24.60 Mil as of Jun. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on MaxCyte and its competitors.
Is MaxCyte's Gross Profit too high?
MaxCyte's current Gross Profit is $24.60 Mil. Overall, MaxCyte has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MaxCyte's Gross Profit compare to STIM and CVRX?
MaxCyte's Gross Profit of $24.60 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Medical Devices & Instruments company?
A good Gross Profit depends on the Medical Devices & Instruments industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on MaxCyte and its competitors. MaxCyte's current Gross Profit is $24.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MaxCyte stock overvalued right now?
Based on GuruFocus' analysis, MaxCyte (MXCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.56, compared to a current price of $1.41 — trading 44.9% below its estimated fair value. The current Gross Profit is $24.60 Mil. MaxCyte's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For MaxCyte (MXCT), the current Gross Profit is $24.60 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MaxCyte (MXCT) Overvalued in 2026?
Based on GuruFocus' analysis, MaxCyte stock appears to be undervalued.
The current stock price of $1.41 is trading 44.9% below its estimated GF Value™ of $2.56.
GuruFocus considers MaxCyte to be Possible Value Trap.
Key valuation signals for MXCT:
Gross Profit: $24.60 Mil
GF Value™: $2.56 vs. price of $1.41 (44.9% below fair value)
No single metric tells the full story. See the MXCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
63GF Score
Get the complete analysis for MXCT
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MXCT has been successfully added to your 
